Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Leronlimab in the patients with metastatic triple-negative breast cancer

Trial Profile

A clinical trial of Leronlimab in the patients with metastatic triple-negative breast cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs Leronlimab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2019 According to a CytoDyn media release, the company will present details of BLA submission of leronlimab and about this trial during Noble Capital Markets 15th annual NobleCon Investor Conference on January 28, 2019 at 4:30 p.m. ET.
    • 07 Jan 2019 Status changed from planning to recruiting, according to a CytoDyn media release.
    • 07 Jan 2019 According to a CytoDyn media release, based on the approval from FDA, the company has initiated this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top